Tadalafil Enhances Immune Signatures in Response to Neoadjuvant Nivolumab in Resectable Head and Neck Squamous Cell Carcinoma
暂无分享,去创建一个
J. Netterville | B. Leiby | A. Argiris | U. Rodeck | M. Mahoney | U. Martinez-outschoorn | Brandee T. Brown | A. Shimada | S. Shukla | R. Zinner | J. Curry | A. Linnenbach | A. South | R. Axelrod | M. Gibson | D. Cognetti | M. Tuluc | S. Gargano | N. Kotlov | S. Degryse | A. Luginbuhl | K. Mannion | J. Johnson | L. Harshyne | Young J Kim | G. Kumar | A. Alnemri | Zoya Antysheva | Jennifer M. Johnson
[1] J. Taube,et al. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial , 2021, Journal for ImmunoTherapy of Cancer.
[2] V. Takiar,et al. Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC). , 2021, Journal of Clinical Oncology.
[3] D. Kallogjeri,et al. Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). , 2021 .
[4] N. Almog,et al. Conserved pan-cancer microenvironment subtypes predict response to immunotherapy. , 2021, Cancer cell.
[5] W. Rubas,et al. NKTR-255, a novel polymer-conjugated rhIL-15 with potent antitumor efficacy , 2021, Journal for ImmunoTherapy of Cancer.
[6] W. William,et al. Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas , 2021, Frontiers in Oncology.
[7] Alexander R. Pico,et al. Proteogenomic insights into the biology and treatment of HPV-negative head and neck squamous cell carcinoma. , 2021, Cancer cell.
[8] B. Leiby,et al. Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect , 2020, Frontiers in Oncology.
[9] R. Tishler,et al. Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma: A Phase 2 Open-Label Randomized Clinical Trial. , 2020, JAMA oncology.
[10] M. Lanuti,et al. Abstract 853: Novel machine learning based deconvolution algorithm results in accurate description of tumor microenvironment from bulk RNAseq , 2020 .
[11] P. Schuler,et al. Circulating Exosomes Inhibit B Cell Proliferation and Activity , 2020, Cancers.
[12] Hui Guo,et al. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis. , 2020, Lung cancer.
[13] J. Hardin,et al. The Association Between Phosphodiesterase-5 Inhibitors and Colorectal Cancer in a National Cohort of Patients , 2020, Clinical and translational gastroenterology.
[14] A. Matakidou,et al. Molecular biomarkers to identify patients (pts) who may benefit from durvalumab (D; anti-PD-L1) ± tremelimumab (T; anti-CTLA-4) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) from HAWK and CONDOR studies. , 2020 .
[15] Fengchun Zhang,et al. Are immune-related adverse events associated with the efficacy of immune checkpoint inhibitors in patients with cancer? A systematic review and meta-analysis , 2020, BMC Medicine.
[16] Jason M. Johnson,et al. Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results , 2020, Clinical Cancer Research.
[17] A. Broeks,et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers , 2020, Nature Medicine.
[18] Zachary L. Skidmore,et al. Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial , 2020 .
[19] J. Taube,et al. Neoadjuvant checkpoint blockade for cancer immunotherapy , 2020, Science.
[20] R. Uchi,et al. Relationship between immune-related adverse events and the long-term outcomes in recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab. , 2019, Oral oncology.
[21] Hung-Ming Wang,et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study , 2019, The Lancet.
[22] Q. Zeng,et al. HPV-positive status associated with inflamed immune microenvironment and improved response to anti-PD-1 therapy in head and neck squamous cell carcinoma , 2019, Scientific Reports.
[23] N. Tinari,et al. Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients. , 2019, Clinical lung cancer.
[24] Dominic Grün,et al. A Human Liver Cell Atlas reveals Heterogeneity and Epithelial Progenitors , 2019, Nature.
[25] C. Gomez-Fernandez,et al. The Reversal of Immune Exclusion Mediated by Tadalafil and an Anti-tumor Vaccine Also Induces PDL1 Upregulation in Recurrent Head and Neck Squamous Cell Carcinoma: Interim Analysis of a Phase I Clinical Trial , 2019, Front. Immunol..
[26] M. Frelaut,et al. Hyperprogression under Immunotherapy , 2019, International journal of molecular sciences.
[27] Sagar,et al. A Human Liver Cell Atlas: Revealing Cell Type Heterogeneity and Adult Liver Progenitors by Single-Cell RNA-sequencing , 2019, bioRxiv.
[28] O. V. Matorin,et al. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study , 2019, The Lancet.
[29] G. Weinstein,et al. Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer , 2018, Clinical Cancer Research.
[30] A. Pearson,et al. Association of immune-related adverse events (irAEs) with improved response, progression-free survival, and overall survival for patients with metastatic head and neck cancer receiving anti-PD-1 therapy. , 2018 .
[31] A. Enk,et al. Tadalafil has biologic activity in human melanoma. Results of a pilot trial with Tadalafil in patients with metastatic Melanoma (TaMe) , 2017, Oncoimmunology.
[32] I. Mellman,et al. Elements of cancer immunity and the cancer–immune set point , 2017, Nature.
[33] J. Radford. Nivolumab for recurrent squamous-cell carcinoma of the head and neck , 2016, BDJ.
[34] M. Smyth,et al. Improved Efficacy of Neoadjuvant Compared to Adjuvant Immunotherapy to Eradicate Metastatic Disease. , 2016, Cancer discovery.
[35] J. Lunceford,et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. , 2016, The Lancet. Oncology.
[36] D. Andrews,et al. Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients. , 2016, Neuro-oncology.
[37] J. Mesirov,et al. The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .
[38] S. Goodman,et al. Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma , 2015, Clinical Cancer Research.
[39] J. Califano,et al. Tadalafil Reduces Myeloid-Derived Suppressor Cells and Regulatory T Cells and Promotes Tumor Immunity in Patients with Head and Neck Squamous Cell Carcinoma , 2014, Clinical Cancer Research.
[40] M. Bui,et al. Targeting Immune Suppression with PDE5 Inhibition in End-Stage Multiple Myeloma , 2014, Cancer Immunology Research.
[41] F. Schmidt. Meta-Analysis , 2008 .
[42] J. Califano,et al. Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function , 2006, The Journal of experimental medicine.
[43] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] Andrew Simon Bell,et al. Sildenafil (VIAGRATM), a potent and selective inhibitor of type 5 cGMP phosphodiesterase with utility for the treatment of male erectile dysfunction , 1996 .
[45] P F Thall,et al. Practical Bayesian guidelines for phase IIB clinical trials. , 1994, Biometrics.